Active — Not RecruitingPhase 4

Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation

Egypt60 participantsStarted 2022-03-15

Plain-language summary

the aim of the study is to approve the hypothesis that dexmedetomidine can protect against glycocalyx degradation induced by hepatic ischemia-reperfusion injury and hence can reduce the subsequent complications as early allograft dysfunction, other organ dysfunction and hemodynamic instability

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients aged 18-60 years.
✓. Model for end-stage liver disease (MELD) score 12-20.
✓. No severe hemodynamic instability.
✓. The liver donors aged 18-50 years and the sum of macro- and microvesicular hepatic steatosis has to be less than 30%.

Exclusion criteria

✕. History of psychiatric/neurological illness.
✕. Cardiovascular disease.
✕. Hypertensive patients.
✕. Morbid obese patients (body mass index (BMI) \> 35).
✕. Chronic obstructive pulmonary disease; pulmonary dysfunction (PaO2 less than 60 mmHg).
✕. Known allergic reaction to any of the study medications.

What they're measuring

syndecan-1 level

Timeframe: 48 hours

Trial details

NCT IDNCT05031026

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-15

View on ClinicalTrials.gov More Liver Transplant; Complications trials